Adopting a Framework for Rapid Real-World Data Analyses in Safety Signal Assessment

The expanding availability of real-world data (RWD) has led to an increase in both the interest and possibilities for using this information in postmarketing safety analyses and signal management. While there is enormous potential value from the safety insights generated through RWD, the analysis preparation, execution, and communication required to reliably deliver the evidence can be time consuming. Since the safety signal assessment process is a regulated and timebound process, any supporting RWD analyses require a rapid turnaround of well-designed and informative results. To address this challenge, a TransCelerate BioPharma working group was formed and developed a framework to help teams responsible for safety signal assessment overcome the challenges of working with RWD rapidly to deliver analyses within regulatory timelines. Here, a previously performed safety assessment was evaluated within the context of the developed framework to illustrate how the framework may be adopted in practice.

Authors

Institutions

Publication Details

Journal
Therapeutic Innovation & Regulatory Science
Published
2024-09-06
DOI
https://doi.org/10.1007/s43441-024-00694-7
Citations
1
Primary Topic
Risk and Safety Analysis
Type
article
Field-Weighted Citation Impact
0.46
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Adopting a Framework for Rapid Real-World Data Analyses in Safety Signal Assessment

Geoffrey Gipson, Julie Barberio, Katrin Manlik, Rachel Fell McDermott et al.
1 citations
Therapeutic Innovation & Regulatory Science
Risk and Safety Analysis
0.46
article

Adopting a Framework for Rapid Real-World Data Analyses in Safety Signal Assessment

Geoffrey Gipson, Julie Barberio, Katrin Manlik, Rachel Fell McDermott, Vaishali Patadia, Stephanie von Klot, Julius Asubonteng, Negar Golchin, Lu Wang, Claudia A. Salinas, Mary K. Miller
article en
1 citations

Abstract

The expanding availability of real-world data (RWD) has led to an increase in both the interest and possibilities for using this information in postmarketing safety analyses and signal management. While there is enormous potential value from the safety insights generated through RWD, the analysis preparation, execution, and communication required to reliably deliver the evidence can be time consuming. Since the safety signal assessment process is a regulated and timebound process, any supporting RWD analyses require a rapid turnaround of well-designed and informative results. To address this challenge, a TransCelerate BioPharma working group was formed and developed a framework to help teams responsible for safety signal assessment overcome the challenges of working with RWD rapidly to deliver analyses within regulatory timelines. Here, a previously performed safety assessment was evaluated within the context of the developed framework to illustrate how the framework may be adopted in practice.

Therapeutic Innovation & Regulatory ScienceVol. 58(6)
Amgen (United States) (US), Johnson & Johnson (United States) (US), Boehringer Ingelheim (Germany) (DE), Eli Lilly (United States) (US), Regeneron (United States) (US), Sanofi (United States) (US), Shionogi (Japan) (JP), La Roche College (US), Bayer (Germany) (DE)
Openalex Percentile: Top 29%
Risk and Safety Analysis
0.46
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Adopting a Framework for Rapid Real-World Data Analyses in Safety Signal Assessment — Geoffrey Gipson, Julie Barberio, et al. · Therapeutic Innovation & Regulatory Science (2024) | TGRS Research Map | TGRS